All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ins and outs of CAR T cells in the real word: Live Hub Event
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
During the EHA 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite session on the ins and outs of CAR T cells in the real world.
Here, we share the presentation by Michael Hudecek, University Hospital Würzburg, Würzburg, DE, discussing answers to common challenges in CAR T-cell therapy.
In this presentation, Hudecek identifies limitations in patient access and inefficient manufacturing protocols as the main challenges currently restricting the scalability of CAR T-cell therapies (Figure 1), before highlighting some possible innovative answers (Figure 2).
Figure 1. The effect of limited patient access on CAR T-cell therapy for patients with DLBCL in Italy*
CAR, chimeric antigen receptor; DLBCL, diffuse large B-cell lymphoma; R/R, relapsed/refractory;
2L, second line.
*Adapted from Jommi, et al.1
Figure 2. The impact of centralized CAR T-cell manufacturing on wait times for CAR T-cell infusion*
CAR, chimeric antigen receptor; PoC, point of care.
*Created with BioRender.com
Watch or download the presentation to learn more about the common challenges and solutions facing CAR T-cell therapy today, including:
This activity was supported through an educational grant from Bristol Myers Squibb.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
The ins and outs of CAR T cells in the real word: Live Hub Event
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox